Tempest Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 19, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 19, 2024

TPST$0.36-5.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

	As of December 31,
	2023	2022
Assets
Current assets:
Cash and cash equivalents	$39,230	$31,230
Insurance recovery of legal settlement	—	450
Prepaid expenses and other current assets	1,133	1,270
Total current assets	40,363	32,950
Property and equipment — net	840	1,060
Operating lease right-of-use assets	9,952	11,650
Other noncurrent assets	448	429
Total assets	$51,603	$46,089
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$845	$1,108
Accrued legal settlement	—	450
Accrued expenses	1,673	2,961
Current loan payable (net of discount and issuance costs of $112 and nil, respectively)	4,285	—
Current operating lease liabilities	952	1,413
Accrued compensation	1,543	1,248
Interest payable	113	97
Total current liabilities	9,411	7,277
Loan payable (net of discount and issuance costs of $164 and $454, respectively)	6,264	10,371
Operating lease liabilities, less current portion	9,160	10,330
Total liabilities	24,835	27,978
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized; 22,045,255 and 10,518,539 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	22	11
Additional paid-in capital	192,009	153,872
Accumulated deficit	(165,263)	(135,772)
Total stockholders’ equity	26,768	18,111
Total liabilities and stockholders’ equity	$51,603	$46,089

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.